COMPLICATIONS OF ANTITUMOR TREATMENT

Pulmonary complications of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with hematological malignancies

COMPLICATIONS OF ANTITUMOR TREATMENT , ,

V.O. Sarzhevskiy, V.Ya. Melnichenko, V.P. Tyurin

N.I. Pirogov National Medico-surgical Center, RF MH, Moscow, Russian Federation

ABSTRACT

This review presents the recent data on the pulmonary complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with hematological malignancies. The detailed information on the diagnostic approaches, pathogenetic and clinical features, prevention and treatment of the early and late pulmonary toxicity is provided.

Keywords: high-dose chemotherapy, autologous hematopoietic stem cell transplantation, pulmonary complications.

Read in PDF (RUS)pdficon

REFERENCES

  1. Prince D.S., Wingard J.R., Saral R. et al. Longitudinal changes in pulmonary function following bone marrow transplantation. Chest 1989; 96(2): 301–6.
  2. Arvidson J., Bratteby L.E., Carlson K. et al. Pulmonary function after autologous bone marrow transplantation in children. Bone Marrow Transplant. 1994; 14(1): 117–23.
  3. Ghalie R., Szidon J.P., Thompson L. et al. Evaluation of pulmonary complications after bone marrow transplantation: the role of pretransplant pulmonary function tests. Bone Marrow Transplant. 1992; 10(4): 359–65.
  4. Nenadov Beck M., Meresse V., Hartmann O. et al. Long-term pulmonary sequelae after autologous bone marrow transplantation in children without total body irradiation. Bone Marrow Transplant. 1995; 16(6): 771–5.
  5. Badier M., Guillot C., Delpierre S. et al. Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant. 1993; 12(5): 457–61.
  6. Ho V.T., Weller E., Lee S.J. et al. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2001; 7(4): 223–9.
  7. Shannon V.R., Andersson B.S., Lei X. et al. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010; 45(4): 647–55.
  8. Hofmeister C.C., Czerlanis C., Forsythe S. et al. Retrospective utility of bronchoscopy after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006; 38(10): 693–8.
  9. Azoulay E., Mokart D., Rabbat A. et al. Diagnostic bronchoscopy in hematology and oncology patients with acute respiratory failure: prospective multicenter data. Crit. Care Med. 2008; 36(1): 100–7.
  10. NCCN Guidelines Version 1.2012. Prevention and Treatment of CancerRelated Infection. 2012: 15.
  11. Sharma S., Nadrous H.F., Peters S.G. et al. Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest. 2005; 128(3): 1385–92.
  12. Roychowdhury M., Pambuccian S.E., Aslan D.L. et al. Pulmonary complications after bone marrow transplantation: an autopsy study from a large transplantation center. Arch. Pathol. Lab. Med. 2005; 129(3): 366–71.
  13. Munker R., Lazarus H.M., Atkinson K. The BMT Data Book, 2nd edn. Cambridge University Press, 2009: 237.
  14. Frankovich J., Donaldson S.S., Lee Y. et al. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin’s disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol. Blood Marrow Transplant. 2001; 7(1): 49–57.
  15. Avivi I., Hardak E., Shaham B. et al. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors. Ann. Hematol. 2012; 91(2): 215–21.
  16. Arimura K., Inoue H., Kukita T. et al. Acute lung Injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica 2005; 90(3): ECR10.
  17. Krishnan G.S., Chaudhary V., Al-Janadi A. et al. BCNU toxicity presenting with a large pericardial and pleural effusion. Ann. Transplant. 2008; 13(1): 44–7.
  18. Jones R.B., Matthes S., Shpall E.J. et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J. Natl. Cancer Inst. 1993; 85(8): 640–7.
  19. Puig N., de la Rubia J., Remigia M.J. et al. Morbidity and transplantrelated mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. Leuk. Lymphoma 2006; 47(8): 1488–94.
  20. Stuart M.J., Chao N.S., Horning S.J. et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin’s disease. Biol. Blood Marrow Transplant. 2001; 7(10): 552–60.
  21. Munker R., Hilderbrandt G.C., Lazarus H.M., Atkinson K. The BMT Data Book: including cellular therapy, 3nd edn. Cambridge University Press, 2013: 282.
  22. Malik S.W., Myers J.L., DeRemee R.A. et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am. J. Respir. Crit. Care Med. 1996; 154(6 Pt. 1): 1851–6.
  23. Chen C.I., Abraham R., Tsang R. et al. Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplant. 2001; 27(2): 177–82.
  24. Afessa B., Abdulai R.M., Kremers W.K. et al. Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. Chest 2012; 141(2): 442–50.
  25. Halaburda K., Nasilowska-Adamska B., Grabarczyk P. et al. Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab. Ann. Transplant. 2007; 12(2): 37–40.
  26. Mariotte E., Schnell D., Scieux C. et al. Significance of herpes-virus 6 in BAL fluid of hematology patients with acute respiratory failure. Infection 2011; 39(3): 225–30.
  27. Robbins R.A., Linder J., Stahl M.G. et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am. J. Med. 1989; 87(5): 511–8.
  28. Afessa B., Tefferi A., Litzow M.R. et al. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am. J. Respir. Crit. Care Med. 2002; 166(5): 641–5.
  29. Metcalf J.P., Rennard S.I., Reed E.C. et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. University of Nebraska Medical Center Bone Marrow Transplant Group. Am. J. Med. 1994; 96(4): 327–34.
  30. Lee C.K., Gingrich R.D., Hohl R.J. et al. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant. 1995; 16(1): 175–82.
  31. Spitzer T.R. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001; 27(9): 893–8.
  32. Edenfield W.J., Moores L.K., Goodwin G. et al. An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose. Bone Marrow Transplant. 2000; 25(4): 405–9.
  33. Nurnberger W., Willers R., Burdach S. et al. Risk factors for capillary leakage syndrome after bone marrow transplantation. Ann. Hematol. 1997; 74(5): 221–4.
  34. Kantrow S.P., Hackman R.C., Boeckh M. et al. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 1997; 63(8): 1079–86.
  35. Clark J.G., Hansen J.A., Hertz M.I. et al. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am. Rev. Respir. Dis. 1993; 147(6 Pt. 1): 1601–6.
  36. Kato H., Yamamoto K., Taji H. et al. Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-Hodgkin lymphoma. Clin. Lymph. Myel. Leuk. 2011; 11(6): 483–9.
  37. Metzner B., Gruneisl R., Gebauer W. et al. Late infectious complications after high-dose therapy and autologous blood stem cell transplantation. Med. Klin. (Munich) 2002; 97(11): 650–8.
  38. Roy V., Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant. 1997; 19(5): 467–70.
  39. Akan H., Arslan O., Akan O.A. et al. Tuberculosis in stem cell transplant patients. J. Hosp. Infect. 2006; 62(4): 421–6.
  40. Marras T.K., Chan C.K. Obliterative bronchiolitis complicating bone marrow transplantation. Semin. Respir. Crit. Care Med. 2003; 24(5): 531–42.
  41. Paz H.L., Crilley P., Patchefsky A., Schiffman R.L., Brodsky I. Bronchiolitis obliterans after autologous bone marrow transplantation. Chest 1992; 101(3): 775–8.
  42. Gulbahce H.E., Pambuccian S.E., Jessurun J. et al. Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis. Am J. Clin. Pathol. 2004; 121(2): 205–10.
  43. Witherspoon R.P., Fisher L.D., Schoch G. et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N. Engl. J. Med. 1989; 321(12): 784–9.
  44. Danner-Koptik K.E., Majhail N.S., Brazauskas R. et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant. 2013; 48(3): 363–8.

Cardiotoxicity of high-dose chemotherapy and autologous hematopoietic cell transplantation in patients with hematological malignancies

COMPLICATIONS OF ANTITUMOR TREATMENT , ,

V.O. Sarzhevsky, D.S. Kolesnikova, V.Ya. Mel’nichenko, and V.P. Tyurin

N.I. Pirogov National Medico-surgical Centre, RF Ministry of Health, Moscow, Russian Federation

ABSTRACT

This review presents the recent data on cardiotoxicity of high-dose chemotherapy and autologous hematopoietic cell transplantation in patients with hematological malignancies. The article includes detailed description of the methods used for cardiotoxicity assessment and clinical features of early and late cardiac complications. Also, the approaches to prevention and treatment of cardiotoxicity in this group of patients are suggested.

Keywords: cardiotoxicity, high-dose chemotherapy, autologous hematopoietic cell transplantation.

Read in PDF (RUS)pdficon

REFERENCES

  1. Phillips G.L., Reece D.E. Clinical studies of autologous bone marrow transplantation in Hodgkin’s disease. Clin. Haematol. 1986; 15(1): 151–66.
  2. Appelbaum F.R., Sullivan K.M., Buckner C.D. et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J. Clin. Oncol. 1987; 5(9): 1340–7.
  3. Cazin B., Gorin N.C., Laporte J.P. et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986; 57(10): 2061–9.
  4. Goldberg M.A., Antin J.H., Guinan E.C. et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68(5): 1114–8.
  5. Murdych T., Weisdorf D.J. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997. Bone Marrow Transplant. 2001; 28(3): 283–7.
  6. Dolci A., Dominici R., Cardinale D. et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am. J. Clin. Pathol. 2008; 130(5): 688–95.
  7. Cardinale D., Sandri M.T., Martinoni A. et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol. 2000; 36(2): 517–22.
  8. Cardinale D., Sandri M.T., Colombo A. et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109(22): 2749–54.
  9. Chung T., Lim W.C., Sy R. et al. Subacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac function. Heart 2008; 94(7): 911–8.
  10. Horacek J.M., Pudil R., Tichy M. et al. Biochemical markers and assessment of cardiotoxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Exp. Oncol. 2007; 29(3): 243–7.
  11. Auner H.W., Tinchon C., Linkesch W. et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann. Hematol. 2003; 82(4): 218–22.
  12. Cardinale D., Colombo A., Sandri M.T. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation 2006; 114(23): 2474–81.
  13. Кардиология. Национальное руководство: краткое издание. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2012. [Kardiologiya. Natsionalnoye rukovodstvo: kratkoye izdaniye. Pod red. Yu.N. Belenkova, R.G. Oganova (Cardiology. National manual: brief edition. Ed. by Yu.N. Belenkova and R.G. Oganova). M.: GEOTAR-Media, 2012.]
  14. Suzuki T., Hayashi D., Yamazaki T. et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. 1998; 136(2): 362–3.
  15. Nousiainen T., Jantunen E., Vanninen E. et al. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur. J. Haematol. 1998; 61(5): 347–53.
  16. Snowden J.A., Hill G.R., Hunt P. et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant. 2000; 26(3): 309–13.
  17. Masuko M., Ito M., Kurasaki T. et al. Plasma brain natriuretic peptide during myeloablative stem cell transplantation. Intern. Med. 2007; 46(9): 551–5.
  18. Zver S., Zadnik V., Bunc M. et al. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int. J. Hematol. 2007; 85(5): 408–14.
  19. Kupari M., Volin L., Suokas A. et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant. 1990; 5(2): 91–8.
  20. Styler M.J., Topolsky D.L., Crilley P.A. et al. Transient high grade heart block following autologous bone marrow infusion. Bone Marrow Transplant. 1992; 10(5): 435–8.
  21. Munker R., Lazarus H. M., Atkinson K. The BMT Data Book, 2nd ed. Cambridge: Cambridge University Press, 2009: 237.
  22. Pihkala J., Saarinen U.M., Lundstrom U. et al. Effects of bone marrow transplantation on myocardial function in children. Bone Marrow Transplant. 1994; 13(2): 149–55.
  23. Zver S., Zadnik V., Cernelc P. et al. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int. J. Hematol. 2008; 88(2): 227–36.
  24. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). М., 2010: 428. [Minimalnye klinicheskiye rekomendatsii Yevropeyskogo obshchestva meditsinskoy onkologii (ESMO) (Minimal clinical recommendations of European Society for Medical Oncology (ESMO)). M., 2010: 428.]
  25. Nagueh S.F., Sua H., Kopelen H.A. et al. Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J. Am. Coll. Cardiol. 2001; 37: 278–85.
  26. Шкляева А.В. Ультразвуковая оценка функционального состояния левого желудочка сердца при высокодозной немиелоаблативной химиотерапии у больных злокачественными лимфомами: Автореф. дис. ¼ канд. мед. наук. Обнинск, 2011.
  27. [Shklyayeva A.V. Ultrazvukovaya otsenka funktsionalnogo sostoyaniya levogo zheludochka serdtsa pri vysokodoznoy nemiyeloablativnoy khimioterapii u bolnykh zlokachestvennymi limfomami: Avtoref. dis. ¼ kand. med. nauk (Ultrasound evaluation of left ventricle function during high-dose nonmyeloablative chemotherapy in patients with malignant lymphomas. Author’s summary of dissertation for the degree of PHD). Obninsk, 2011.]
  28. Kuittinen T., Husso-Saastamoinen M., Sipola P. et al. Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin’s lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2005; 36(12): 1077–82.
  29. Bosch X., Esteve J., Sitges M. et al. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. J. Card. Fail. 2011; 17(8): 643–8.
  30. Gustavsson A., Eskilsson J., Landberg T. et al. Late cardiac effects after mantle radiotherapy in patients with Hodgkin’s disease. Ann. Oncol. 1990; 1: 355–63.
  31. Girinsky T., Cordova A., Rey A. et al. Thallium-201 scintigraphy is not predictive of late cardiac complications in patients with Hodgkin’s disease treated with mediastinal radiation. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48: 1503–6.
  32. Glanzmann C., Kaufmann P., Jenni R. et al. Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother. Oncol. 1998; 46: 51–62.
  33. Salloum E., Jillella A.P., Nadkarni R. et al. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 1998; 82(8): 1506–12.
  34. Hertenstein B., Stefanic M., Schmeiser T. et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J. Clin. Oncol. 1994; 12(5): 998–1004.
  35. Herbay A., Dorken B., Mall G. et al. Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor. Klin. Wochenschr. 1988; 66(23): 1175–81.
  36. Bearman S.I., Petersen F.B., Schor R.A. et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant. 1990; 5(3): 173–7.
  37. Lehmann S., Isberg B., Ljungman P. et al. Cardiac systolic function before and after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000; 26(2): 187–92.
  38. Armenian S.H., Sun C.L., Shannon T. et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood 2011; 118(23): 6023–9.
  39. Schouten H.C., Maragos D., Vose J. et al. Diabetes mellitus or an impaired glucose tolerance as a potential complicating factor in patients treated with high-dose therapy and autologous bone marrow transplantation. Bone Marrow Transplant. 1990; 6(5): 333–5.
  40. Atkinson K. (ed.) Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd ed. Cambridge: Cambridge University Press, 2000: 1111.
  41. Stillwell E.E., Wessler J.D., Rebolledo B.J. et al. Retrospective outcome data for hematopoietic stem cell transplantation in patients with concurrent coronary artery disease. Biol. Blood Marrow Transplant. 2011; 17(8): 1182–6.
  42. Tyndall A., Passweg J., Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann. Rheum. Dis. 2001; 60(7): 702–7.
  43. Eckman P.M., Bertog S.C., Wilson R.F. et al. Ischemic cardiac complications following G-CSF. Catheter. Cardiovasc. Interv. 2010; 76(1): 98–101.
  44. Nakane T., Nakamae H., Koh H. et al. Heart rate variability during and after peripheral blood stem cell leukapheresis in autologous transplant patients and allogeneic transplant donors. Int. J. Hematol. 2010; 91(3): 478–84.
  45. Ulrickson M., Aldridge J., Kim H.T. et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Biol. Blood Marrow Transplant. 2009; 15(11): 1447–54.
  46. Reece D.E., Nevill T.J., Sayegh A. et al. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16–213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease. Bone Marrow Transplant. 1999; 23(11): 1131–8.
  47. Rosenthal M.A., Grigg A.P., Sheridan W.P. High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. Leuk. Lymphoma 1994; 14(3–4): 279–83.
  48. Kim J.W., Lee H.J., Yi H.G. et al. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. Am. J. Hematol. 2012; 87(5): 479–83.
  49. Ferrara F., Palmieri S., Pedata M. et al. Autologous stem cell transplantation for elderly patients with acute myeloid leukaemia conditioned with continuous infusion idarubicin and busulphan. Hematol. Oncol. 2009; 27(1): 40–5.
  50. Krishnan G.S., Chaudhary V., Al-Janadi A. et al. BCNU toxicity presenting with a large pericardial and pleural effusion. Ann. Transplant. 2008; 13(1): 44–7.
  51. Mileshkin L.R., Seymour J.F., Wolf M.M. et al. Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for patients aged 60 years and older. Leuk. Lymphoma 2005; 46(11): 1575–9.
  52. Sirohi B., Powles R., Treleaven J. et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant. 2000; 25(5): 533–9.
  53. Davis J., Rowley S.D., Santos G.W. Toxicity of autologous bone marrow graft infusion. Prog. Clin. Biol. Res. 1990; 333: 531–40.
  54. Galmes A., Gutierrez A., Sampol A. et al. Long-term hematological reconstitution and clinical evaluation of autologous peripheral blood stem cell transplantation after cryopreservation of cells with 5% and 10% dimethylsulfoxide at 80 degrees C in a mechanical freezer. Haematologica 2007; 92(7): 986–9.
  55. Rapoport A.P., Rowe J.M., Packman C.H. et al. Cardiac arrest after autologous marrow infusion. Bone Marrow Transplant. 1991; 7(5): 401–3.
  56. Martino M., Morabito F., Messina G. et al. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haematologica 1996; 81(1): 59–61.
  57. Donmez A., Zoghi M., Cagirgan S. et al. The effect of hematopoietic progenitor cells’ temperature on cardiac arrhythmias in patients given peripheral blood progenitor cells. Transfus. Apher. Sci. 2006; 34(3): 245–51.
  58. Quinn J.P., Counts G.W., Meyers J.D. Intracardiac infections due to coagulase-negative Staphylococcus associated with Hickman catheters. Cancer 1986; 57(5): 1079–82.
  59. Martino P., Micozzi A., Venditti M. et al. Catheter-related right-sided endocarditis in bone marrow transplant recipients. Rev. Infect. Dis. 1990; 12(2): 250–7.
  60. Philip T., Biron P., Herve P. et al. Massive BACT chemotherapy with autologous bone marrow transplantation in 17 cases of non-Hodgkin’s malignant lymphoma with a very bad prognosis. Eur. J. Cancer Clin. Oncol. 1983; 19(10): 1371–9.
  61. Guerin C., Billard J.L., Jaubert J. et al. Pericardial aspergillosis in a bone marrow transplant recipient. Intens. Care Med. 1989; 15(5): 330.
  62. Ellerbroek P., Kuipers S., Rozenberg-Arska M. et al. Oerskovia xanthineolytica: a new pathogen in bone marrow transplantation. Bone Marrow Transplant. 1998; 22(5): 503–5.
  63. Bhatia S., Robison L.L., Francisco L. et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005; 105(11): 4215–22.
  64. Lavoie J.C., Connors J.M., Phillips G.L. et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106(4): 1473–8.
  65. Ruiz-Soto R., Sergent G., Gisselbrecht C. et al. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer 2005; 104(12): 2735–42.
  66. Silber J.H., Cnaan A., Clark B.J. et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J. Clin. Oncol. 2004; 22(5): 820–8.
  67. Lipshultz S.E., Lipsitz S.R., Sallan S.E. et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J. Clin. Oncol. 2002; 20(23): 4517–22.
  68. Kakavas P.W., Ghalie R., Parrillo J.E. et al. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant. 1995; 15(6): 859–61

Cardiovascular complications of chronic myeloid leukemia treated with tyrosine kinase inhibitors

COMPLICATIONS OF ANTITUMOR TREATMENT , , ,

G.E. Gendlin, L.M. Makeeva, E.I. Emelina, K.V. Shuikova, G.I. Storozhakov

 FGEI HPE RNRMU named after N.I. Pirogov of Russian MoH, Moscow, Russian Federation

ABSTRACT

The achieved nowadays success in oncohematology patients’ treatment is primarily associated with the development of targeted therapy, including invention of specific tyrosine kinase inhibitors for chronic myeloid leukemia treatment (imatinib, nilotinib and dasatinib,). However, along with the high efficacy, these medicines have certain toxicities. Cardiovascular complications of tyrosine kinase inhibitors therapy of chronic myeloid leukemia are described in this review article. Taking onto consideration the fact that therapy with these medicines can cause rear but serious side effects. It is necessary to consider the probability of cardiotoxicity, arterial occlusion of various diameter and pulmonary hypertension development before prescription. In order to minimize side effects patients examination is recommended before treatment initiation for recognition of initial cardiovascular diseases, as well as thorough control of cardiovascular condition throughout the treatment.

Keywords: chronic myeloid leukemia, tyrosine kinase inhibitors, cardiac toxicity, targeted therapy

 Read in  PDF (RUS)pdficon

REFERENCES

  1. Емелина Е.И., Шуйкова К.В., Сторожаков Г.И. и др. Поражения сердца при лечении современными противоопухолевыми препаратами и лучевые повреждения сердца у больных с лимфомами. Клин. онкогематол. 2009; 2(2): 152–60. [Emelina E.I., Shuikova K.V., Storozhakov G.I. i dr. Porazheniya serdtsa pri lechenii sovremennymi protivoopukholevymi preparatami i luchevye povrezhdeniya serdtsa u bol’nykh s limfomami (Heart diseases in the modern anti-tumor agent treatment and radiation-induced heart lesions in lymphoma patients). Klin. onkogematol. 2009; 2(2): 152–60.]
  2. Гендлин Г.Е., Сторожаков Г.И., Шуйкова К.В. и др. Острые сердечнососудистые события во время применения противоопухолевых химиопрепаратов: клинические наблюдения. Клин. онкогематол. 2011; 4(2): 155–64. [Gendlin G.E., Storozhakov G.I., Shuikova K.V. i dr. Ostrye serdechnososudistye sobytiya vo vremya primeneniya protivoopukholevykh khimiopreparatov: klinicheskie nablyudeniya (Acute cardiovascular events during treatment with anti-tumor chemotherapeutic agents: clinical observations). onkogematol. 2011; 4(2): 155–64.]
  3. Емелина Е.И., Сторожаков Г.И., Гендлин Г.Е. и др. Случай антрациклин-индуцированной кардиомиопатии после лечения диффузной крупноклеточной В-клеточной лимфомы по схеме АСОР и лучевой терапии. Сердечная недостаточность 2006; 4(38): 202–4. [Emelina E.I., Storozhakov G.I., Gendlin G.E. i dr. Sluchai antratsiklin-indutsirovannoi kardiomiopatii posle lecheniya diffuznoi krupnokletochnoi V-kletochnoi limfomy po skheme ASOR i luchevoi terapii (A case of an anthracycline-induced cardiomyopathy after the ACOP treatment of diffuse large B-cell lymphoma). Serdechnaya nedostatochnost’ 2006; 4(38): 202–4.]
  4. Hare J.M. The Dilated, Restrictive, and Infiltrative Cardiomyopathies. In: Braunwald’s heart disease: A Textbook of Cardiovascular Medicine, 8th Edition, 2008.
  5. ACC/AHA 2005 Guidelines Update for the Diagnosis and Management of Chronic Heart Failure in the Adult.
  6. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. J. Am. Soc. Echocardiogr. 2011; 24: 229–67.
  7. Nuclear Cardiology and Cardiac CT. Berlin, May 5–8, 2013.
  8. Домнинский Д.А. Основы таргетной терапии. Онкогематология 2012; 1: 46–54. [Domninskii D.A. Osnovy targetnoi terapii (Fundamentals of targeted therapy). Onkogematologiya 2012; 1: 46–54.]
  9. Hughes T.P., Kaeda J., Branford S. et al. Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia. New Engl. J. Med. 2003; 349: 1423–32.
  10. National comprehensive cancer network NCCN clinical practice guidelines in oncology: Chronic myelogenous leukemia: Version 2. Fort Washington, PA,
  11. Chen M.H., Kerkela R., Forse T. et al. Mechanisms of cardiac dysfunction associated with tirosine kinase inhibitor cancer therapeutics. Circulation 2008; 118: 84–95.
  12. Kerkela R., Grazette I., Yacolti R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006; 12(8).
  13. Ederhy S., Izzedine H., Massard C. et al. Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Crit. Rev. Oncol. Hematol. 2011: 369–79.
  14. Pinilla-Ibarz J., Cortes J., Mauro M.J. et al. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer 2011; 117: 688–97.
  15. Kantarjian H.M., Shah N.P., Cortes J.E. et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123–9.
  16. Porkka K., Khoury H.J., Paquette R. et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116: 377–86.
  17. Kantarjian H., Shah N.P., Hochhaus A. et al. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. New Engl. J. Med. 2010.
  18. Saglio G., Hochhaus A., Cortes J.E. et al. Safety and Efficacy of Dasatinib Versus Imatinib by Baseline Cardiovascular Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CMLCP): Analysis of the DASISION Trial. ASH 2010. Poster 2286.
  19. Rasheed W., Flaim B., Symour J.F. et al. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk. Res. 2009; 33: 860–9.
  20. EMEA: Sprycel-Scientific discussion. European Public Assessment Report (EPAR 2011).
  21. Quintas-Cardama A., Kantarjian H., O’Brien S. et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. Clin. Oncol. 2007; 25(25): 3908–14.
  22. Mattei D., Feola M., Orzan F. et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 2009; 43(12): 967–8.
  23. Dumitrescu D., Seck C., ten Freyhaus H. et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Respir. J. 2011; 38(1): 218–20.
  24. Hennigs J.K., Keller G., Baumann H.J. et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm. Med. 2011; 23: 11–30.
  25. Orlandi E.M., Rocca B., Pazzano A.S. et al. Reversible pulmonary arterial hypertension likely related to long-term, low dose dasatinib treatment for chronic myeloid leukemia. Leuk. Res. 2012; 36(81): 4–6.
  26. Breccia M., Efficace F., Alimena G. et al. Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: Who’s afraid of the big bad wolf? Res. 2012; 36: 813–4.
  27. Montani D., Bergot E., Ganter S. et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125(17): 2128–37.
  28. Philibert L., Cazorla C., Peyrire H. et al. Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib (Abstract). Fundam. Clin. Pharmacol. 2011; 25(Suppl. 1): 95.
  29. Aichberger K.J., Herndlhofer S., Schernthaner G.-H. et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Hematology 2011; 86: 533–9.